GLP-1 medications like Ozempic and Zepbound are transforming chronic disease and weight management, with perimenopausal women ...

Recently released results from a clinical trial on orforglipron show that the oral medication can cause impressive weight ...

ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the ...

Les agonistes du récepteur du peptide-1 de type glucagon (GLP-1) [aussi appelés « glutides »] sont efficaces pour traiter le diabète de type 2 et la néphropathie chronique Dans un essai contrôlé ...

Eli Lilly announces positive results from phase 3 ATTAIN-1 trial of orforglipron, an oral GLP-1 receptor agonist to treat obesity: Indianapolis Friday, August 8, 2025, 09:00 Hrs [ ...

By Dennis Thompson HealthDay ReporterFRIDAY, Aug. 8, 2025 (HealthDay News) — More than 1 in 10 Americans have used a GLP-1 ...

Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted predominantly by intestinal enteroendocrine L cells in response to nutrient ingestion. By enhancing insulin secretion, delaying ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 global studies. Researchers found that although these medications, including ...

(HealthDay News) — A considerable proportion of adolescents and young adults eligible for glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are uninsured, and many young adults do not have a ...

Results confirm previous findings that nonarteritic anterior ischemic optic neuropathy (NAION) was more likely in those who ...

The glucagon-like peptide 1 market size has grown strongly in recent years. It will grow from $20.88 billion in 2024 to $22.37 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The ...

The glucagon-like peptide 1 (GLP-1) market is projected to grow at a CAGR of 6.48%, during the forecast period of 2022-2027.